0001209191-21-029081.txt : 20210429
0001209191-21-029081.hdr.sgml : 20210429
20210429175625
ACCESSION NUMBER: 0001209191-21-029081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210427
FILED AS OF DATE: 20210429
DATE AS OF CHANGE: 20210429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williams Donald Allen
CENTRAL INDEX KEY: 0001620013
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33672
FILM NUMBER: 21872568
MAIL ADDRESS:
STREET 1: C/O PRYOR CASHMAN LLP
STREET 2: 7 TIMES SQUARE
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALISADE BIO, INC.
CENTRAL INDEX KEY: 0001357459
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 522007292
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 20271 GOLDENROD LANE
STREET 2: STE 2024
CITY: GERMANTOWN
STATE: MD
ZIP: 20876
BUSINESS PHONE: 301-366-4841
MAIL ADDRESS:
STREET 1: 20271 GOLDENROD LANE
STREET 2: STE 2024
CITY: GERMANTOWN
STATE: MD
ZIP: 20876
FORMER COMPANY:
FORMER CONFORMED NAME: Seneca Biopharma, Inc.
DATE OF NAME CHANGE: 20200127
FORMER COMPANY:
FORMER CONFORMED NAME: Neuralstem, Inc.
DATE OF NAME CHANGE: 20060324
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-27
0
0001357459
PALISADE BIO, INC.
PALI
0001620013
Williams Donald Allen
C/O PALISADE BIO, INC.
5800 ARMADA DR., SUITE 210
CARLSBAD
CA
92008
1
0
0
0
Stock Option (Right to Buy)
41.20
2021-04-27
4
A
0
10203
A
2029-06-19
Common Stock
10203
10203
D
Stock Option (Right to Buy)
26.85
2021-04-27
4
A
0
4406
A
2030-07-10
Common Stock
4406
4406
D
The stock option vested in four equal quarterly installments from June 30, 2019.
Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.
The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020.
Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share.
/s/ JD Finley, Attorney-in-Fact for Don Williams
2021-04-29